Novartis (NVS) has released an update.
Novartis has reported a robust third quarter in 2024, showcasing a 10% increase in net sales and a 20% rise in core operating income, driven by strong performances from key drugs like Entresto and Cosentyx. The company has raised its full-year guidance, reflecting confidence in its growth prospects and innovation milestones, including significant FDA approvals. With a free cash flow surge to USD 6 billion, Novartis demonstrates operational excellence and strategic focus on high-growth therapeutic areas.
For further insights into NVS stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
